HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 315 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,977,075 | -43.2% | 313,536 | -46.3% | 1.14% | -31.1% |
| Q2 2023 | $21,073,825 | -19.8% | 584,248 | -15.1% | 1.65% | -30.2% |
| Q1 2023 | $26,282,587 | -50.0% | 688,206 | -25.4% | 2.37% | -51.5% |
| Q4 2022 | $52,525,471 | +42.5% | 923,119 | -1.0% | 4.88% | +30.7% |
| Q3 2022 | $36,861,000 | -11.0% | 932,244 | -1.0% | 3.73% | -22.6% |
| Q2 2022 | $41,415,000 | -35.0% | 941,245 | -41.1% | 4.82% | -14.2% |
| Q1 2022 | $63,709,000 | +4.8% | 1,597,529 | +5.7% | 5.62% | +29.1% |
| Q4 2021 | $60,791,000 | +1.1% | 1,511,843 | +2.3% | 4.35% | +9.9% |
| Q3 2021 | $60,105,000 | -35.4% | 1,477,496 | -27.9% | 3.96% | -29.1% |
| Q2 2021 | $93,103,000 | +11.0% | 2,050,273 | +1.9% | 5.59% | +0.5% |
| Q1 2021 | $83,853,000 | -23.7% | 2,011,350 | -21.8% | 5.56% | -31.6% |
| Q4 2020 | $109,846,000 | +119.2% | 2,571,892 | +34.9% | 8.13% | +58.3% |
| Q3 2020 | $50,110,000 | +28.1% | 1,906,789 | +30.7% | 5.13% | +12.7% |
| Q2 2020 | $39,104,000 | +33.3% | 1,458,545 | -10.6% | 4.56% | -9.0% |
| Q1 2020 | $29,334,000 | -2.7% | 1,630,591 | -4.1% | 5.01% | +29.9% |
| Q4 2019 | $30,155,000 | +15.5% | 1,700,782 | +1.1% | 3.85% | -2.3% |
| Q3 2019 | $26,099,000 | +42.3% | 1,682,745 | +57.6% | 3.94% | +54.9% |
| Q2 2019 | $18,345,000 | -22.6% | 1,067,813 | -27.4% | 2.55% | -17.3% |
| Q1 2019 | $23,691,000 | +72.6% | 1,471,498 | +56.8% | 3.08% | +40.6% |
| Q4 2018 | $13,729,000 | -14.7% | 938,399 | +6.0% | 2.19% | -15.7% |
| Q3 2018 | $16,090,000 | +7.2% | 885,523 | -0.5% | 2.60% | +11.1% |
| Q2 2018 | $15,010,000 | +52.3% | 889,729 | +76.9% | 2.34% | +8.0% |
| Q1 2018 | $9,854,000 | +4.0% | 503,029 | +7.6% | 2.16% | -16.7% |
| Q4 2017 | $9,475,000 | +22.4% | 467,646 | +4.9% | 2.60% | +6.0% |
| Q3 2017 | $7,744,000 | +45.0% | 445,846 | +7.0% | 2.45% | +36.8% |
| Q2 2017 | $5,341,000 | -0.6% | 416,579 | +0.5% | 1.79% | -12.6% |
| Q1 2017 | $5,373,000 | – | 414,611 | – | 2.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |